CB-839
Drug timelines are a Plus or Pro feature.
8 regulatory and trial events tracked for CB-839, covering 2017-02-09 to 2024-12-19. Get the full timeline:
Most recent: Clinical Trial Update: CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer [Phase 1, Phase 2]